ArticleThe Lancet. Oncology2016

HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.

Jason W D Hearn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.